BioSolutions es una empresa mexicana e innovadora que ha desarrollado y patentado una tecnología para producir bioplásticos sustentables mediante el uso de fibras ricas en celulosa
Location: Mexico, Nuevo León, San Pedro Garza García
Employees: 11-50
Phone: +52 81 8363 7006
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | SV Latam C... | svlatamcap... |
Mentions in press and media 12
| Date | Title | Description |
| 13.01.2025 | Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola | This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 millionProgram progress and performance triggers $16.7 million contract option GAITHERS... |
| 16.12.2024 | Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) | GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Res... |
| 05.12.2024 | Autoimmunity BioSolutions: $2 Million (Seed) Closed For Advancing Development Of Immuno-Corrective Therapy For Disease Treatment | Autoimmunity BioSolutions (ABS)—a biotechnology company pioneering a next-generation, immuno-corrective therapy for a genetically defined subpopulation of patients suffering from autoimmune disease—announced the closing of a seed financing ... |
| 28.11.2024 | Autoimmunity BioSolutions Raises $2M in Seed Funding | Autoimmunity BioSolutions, a Houston, TX-based biotechnology company advancing immuno-corrective therapies, raised $2M in Seed funding. The round was led by Eos BioInnovation, with participation from Alexandria Venture Investments, Independ... |
| 26.09.2024 | Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts | GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sus... |
| 26.09.2024 | Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts | GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sus... |
| 31.07.2024 | Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million | GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a global pharmaceutical company, for a purcha... |
| 20.06.2024 | Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million | GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharma... |
| 28.11.2023 | Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) | - |
| 15.02.2023 | Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million | - |
Show more